Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbbVieABBV -0.54%77 12-1 Month Momentum % is 19.59% as of Aug. 16, 2026. GuruFocus rates ABBV with a GF Score™ of 77/100 and a GF Value™ of $218.67 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,019 Drug Manufacturers companies, AbbVie ranks better than 79.2% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-16), AbbVie's 12-1 Month Momentum % is 19.59%.
The industry rank for AbbVie's 12-1 Month Momentum % or its related term are showing as below:
ABBV's 12-1 Month Momentum % is ranked better than 79.2% of 1019
companies
in the Drug Manufacturers industry
Industry Median: -13.18
vs ABBV: 19.59
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
AbbVie 12-1 Month Momentum % Related Terms
ABBV vs MRK, JNJ, AMGN: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, AbbVie's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where AbbVie's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie (ABBV) has a 12-1 Month Momentum % of 19.59% as of Aug. 16, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on AbbVie and its competitors. According to the industry distribution chart, AbbVie ranks #212 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is AbbVie's 12-1 Month Momentum % too high?
AbbVie's current 12-1 Month Momentum % is 19.59%. Based on the distribution chart, AbbVie ranks #212 out of 1019 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AbbVie has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's 12-1 Month Momentum % compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #212 out of 1019 companies for 12-1 Month Momentum %. This places AbbVie in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on AbbVie and its competitors. AbbVie's current 12-1 Month Momentum % is 19.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is $218.67, compared to a current price of $249.46 — trading 14.1% above its estimated fair value. The current 12-1 Month Momentum % is 19.59%. AbbVie's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For AbbVie (ABBV), the current 12-1 Month Momentum % is 19.59% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of $249.46 is trading 14.1% above its estimated GF Value™ of $218.67.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for ABBV:
12-1 Month Momentum %: 19.59%
GF Value™: $218.67 vs. price of $249.46 (14.1% above fair value)
No single metric tells the full story. See the ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
77GF Score
Get the complete analysis for ABBV
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABBV has been successfully added to your 
